Effects of topical prostaglandin therapy on corneal layers thickness in primary open-angle glaucoma patients using anterior segment optical coherence tomography
ConclusionTopical treatment with latanoprost, bimatoprost, and travoprost affects each layer of the cornea separately according to the active and protective substances contained in these eye drops. On the other hand, the thinning effect on the corneal layers was similar in these three drugs because there was no significant difference between the three groups in the total amount of thinning of the corneal layers during the follow-up period. (Source: International Ophthalmology)
Source: International Ophthalmology - April 17, 2023 Category: Opthalmology Source Type: research
Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review
Journal of Ocular Pharmacology and Therapeutics, Ahead of Print. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - April 4, 2023 Category: Opthalmology Authors: Philippe Daull Jean-S ébastien Garrigue Hong Liang Christophe Baudouin Source Type: research
A triple crosslinked micelle-hydrogel lacrimal implant for localized and prolonged therapy of glaucoma
In conclusion, the triple crosslinked micelle-hydrogel lacrimal implant could effectively lower the IOP with splendid compatibility, demonstrating the promising prospect in the long-term noninvasive treatment of glaucoma.PMID:36841507 | DOI:10.1016/j.ejpb.2023.02.011 (Source: European Journal of Pharmaceutics and Biopharmaceutics)
Source: European Journal of Pharmaceutics and Biopharmaceutics - February 25, 2023 Category: Drugs & Pharmacology Authors: Jingyi Zhao Jian Xiong Yun Ning Jiansong Zhao Zhipeng Wang Linhui Long Haibing He Jingxing Gou Tian Yin Xing Tang Yu Zhang Source Type: research
A triple crosslinked micelle-hydrogel lacrimal implant for localized and prolonged therapy of glaucoma
In conclusion, the triple crosslinked micelle-hydrogel lacrimal implant could effectively lower the IOP with splendid compatibility, demonstrating the promising prospect in the long-term noninvasive treatment of glaucoma.PMID:36841507 | DOI:10.1016/j.ejpb.2023.02.011 (Source: European Journal of Pharmaceutics and Biopharmaceutics)
Source: European Journal of Pharmaceutics and Biopharmaceutics - February 25, 2023 Category: Drugs & Pharmacology Authors: Jingyi Zhao Jian Xiong Yun Ning Jiansong Zhao Zhipeng Wang Linhui Long Haibing He Jingxing Gou Tian Yin Xing Tang Yu Zhang Source Type: research
FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma
Exp Eye Res. 2023 Feb 18:109415. doi: 10.1016/j.exer.2023.109415. Online ahead of print.ABSTRACTProstaglandin (PG) receptors represent important druggable targets due to the many diverse actions of PGs in the body. From an ocular perspective, the discovery, development, and health agency approvals of prostaglandin F (FP) receptor agonists (FPAs) have revolutionized the medical treatment of ocular hypertension (OHT) and glaucoma. FPAs, such as latanoprost, travoprost, bimatoprost, and tafluprost, powerfully lower and control intraocular pressure (IOP), and became first-line therapeutics to treat this leading cause of blindn...
Source: Experimental Eye Research - February 21, 2023 Category: Opthalmology Authors: Najam A Sharif Noriko Odani-Kawabata Fenghe Lu Leonard Pinchuk Source Type: research
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis
CONCLUSION: STN1013001 is potentially highly cost-effective and strongly dominant vs. Latanoprost for OAG/OHT+OSD patients from the INHS perspective. These findings should be re-assessed using the data from the ongoing Phase III trial (NCT04133311) comparing the efficacy and safety of STN1013001 vs. Latanoprost and with future real-world CUAs upon the availability of STN1013001 on the Italian market.PMID:36576091 | DOI:10.1080/14737167.2023.2161515 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 28, 2022 Category: Health Management Authors: Carlo Lazzaro C écile van Steen Giorgio Ghirelli Matteo Sacchi Dario Sisto Maurizio Uva Luigi Varano Luigi Angelillo Source Type: research
[ASAP] Latanoprost-Loaded Nanotransfersomes Designed for Scalp Administration Enhance Keratinocytes Proliferation
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00796 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - December 12, 2022 Category: Drugs & Pharmacology Authors: Eloy Pena-Rodri ́guez, Laura García-Vega, Maria Lajarin Reinares, Marçal Pastor-Anglada, Sandra Pérez-Torras, and Francisco Fernandez-Campos Source Type: research
The Effect of Latanoprost on Choroidal Vascularity Index in Glaucoma and Ocular Hypertension
Précis:
The choroidal vascularity index (CVI) is a new marker for the choroid. The decrease in CVI following latanoprost use can provide a better understanding of the pathogenesis of the posterior segment side effects of latanoprost such as cystoid macular edema and central serous choroidopathy.
Purpose:
The purpose of this paper is to evaluate the changes in the CVI, total choroidal area (TCA), stromal area (SA), luminal area (LA), and choroidal thickness (CT) following latanoprost therapy in patients with primary open angle glaucoma and ocular hypertension.
Materials and Methods:
Patients with newly di...
Source: Journal of Glaucoma - December 1, 2022 Category: Opthalmology Tags: Novel Glaucoma Insights: Original Studies Source Type: research
